{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:56:35Z","timestamp":1775152595433,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1038\/sj.bjc.6605726","type":"journal-article","created":{"date-parts":[[2010,6,29]],"date-time":"2010-06-29T22:55:02Z","timestamp":1277852102000},"page":"12-17","source":"Crossref","is-referenced-by-count":79,"title":["A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and\/or paclitaxel in patients with solid tumours"],"prefix":"10.1038","volume":"103","author":[{"given":"U","family":"Lassen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L R","family":"Molife","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S-A","family":"Engelholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R T","family":"Penson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Buhl-Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Tjornelund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Knoblauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J S","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,6,15]]},"reference":[{"key":"BF6605726_CR1","first-page":"1723","volume":"5","author":"KN Bhalla","year":"1999","unstructured":"Bhalla KN, Kumar GN, Walle UK, Ibrado AM, Javed T, Stuart RK, Reed C, Arbuck SG, Walle T (1999) Phase I and pharmacologic study of a 3-h infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res 5: 1723\u20131730","journal-title":"Clin Cancer Res"},{"key":"BF6605726_CR2","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden JE, Peart MJ, Johnstone RW (2006b) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769\u2013784","journal-title":"Nat Rev Drug Discov"},{"key":"BF6605726_CR3","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748\u20131756","journal-title":"J Clin Oncol"},{"key":"BF6605726_CR4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1600-0609.2008.01102.x","volume":"81","author":"P Gimsing","year":"2008","unstructured":"Gimsing P, Hansen M, Knudsen LM, Knoblauch P, Christensen IJ, Ooi CE, Buhl-Jensen P (2008) A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol 81: 170\u2013176","journal-title":"Eur J Haematol"},{"key":"BF6605726_CR5","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1158\/1078-0432.CCR-04-2144","volume":"11","author":"JR Goffin","year":"2005","unstructured":"Goffin JR, Anderson IC, Supko JG, Eder Jr JP, Shapiro GI, Lynch TJ, Shipp M, Johnson BE, Skarin AT (2005) Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res 11: 3417\u20133424","journal-title":"Clin Cancer Res"},{"key":"BF6605726_CR6","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/38664","volume":"389","author":"M Grunstein","year":"1997","unstructured":"Grunstein M (1997) Histone acetylation in chromatin structure and transcription. Nature 389: 349\u2013352","journal-title":"Nature"},{"key":"BF6605726_CR7","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-79-4-604","volume":"79","author":"RW Jelliffe","year":"1973","unstructured":"Jelliffe RW (1973) Letter: creatinine clearance: bedside estimate. Ann Intern Med 79: 604\u2013605","journal-title":"Ann Intern Med"},{"key":"BF6605726_CR8","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1042\/BJ20070779","volume":"409","author":"N Khan","year":"2008","unstructured":"Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 409: 581\u2013589","journal-title":"Biochem J"},{"key":"BF6605726_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jcb.20045","volume":"92","author":"DC Marchion","year":"2004","unstructured":"Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN (2004) Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 92: 223\u2013237","journal-title":"J Cell Biochem"},{"key":"BF6605726_CR10","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1158\/1535-7163.MCT-05-0194","volume":"4","author":"DC Marchion","year":"2005","unstructured":"Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN (2005) In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther 4: 1993\u20132000","journal-title":"Mol Cancer Ther"},{"key":"BF6605726_CR11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/35106079","volume":"1","author":"P Marks","year":"2001","unstructured":"Marks P, Rifkind RA, Richon VM (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194\u2013202","journal-title":"Nat Rev Cancer"},{"key":"BF6605726_CR12","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1517\/13543784.14.12.1497","volume":"14","author":"PA Marks","year":"2005","unstructured":"Marks PA, Dokmanovic M (2005) Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 14: 1497\u20131511","journal-title":"Expert Opin Investig Drugs"},{"key":"BF6605726_CR13","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1200\/JCO.2006.08.6165","volume":"25","author":"P Munster","year":"2007","unstructured":"Munster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A (2007) Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 25: 1979\u20131985","journal-title":"J Clin Oncol"},{"key":"BF6605726_CR14","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/sj.bjc.6605293","volume":"101","author":"PN Munster","year":"2009","unstructured":"Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, Daud A (2009) Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer 101: 1044\u20131050","journal-title":"Br J Cancer"},{"key":"BF6605726_CR15","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/j.1552-4604.1988.tb03134.x","volume":"28","author":"S Oguri","year":"1988","unstructured":"Oguri S, Sakakibara T, Mase H, Shimizu T, Ishikawa K, Kimura K, Smyth RD (1988) Clinical pharmacokinetics of carboplatin. J Clin Pharmacol 28: 208\u2013215","journal-title":"J Clin Pharmacol"},{"key":"BF6605726_CR16","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1158\/1078-0432.CCR-05-2095","volume":"12","author":"RL Piekarz","year":"2006","unstructured":"Piekarz RL, Frye AR, Wright JJ, Steinberg SM, Liewehr DJ, Rosing DR, Sachdev V, Fojo T, Bates SE (2006) Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 12: 3762\u20133773","journal-title":"Clin Cancer Res"},{"key":"BF6605726_CR17","first-page":"721","volume":"2","author":"JA Plumb","year":"2003","unstructured":"Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, La Thangue NB, Brown R (2003) Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2: 721\u2013728","journal-title":"Mol Cancer Ther"},{"key":"BF6605726_CR18","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1158\/1535-7163.MCT-06-0111","volume":"5","author":"X Qian","year":"2006","unstructured":"Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, Sehested M, Lichenstein HS, Jeffers M (2006) Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 5: 2086\u20132095","journal-title":"Mol Cancer Ther"},{"key":"BF6605726_CR19","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1158\/1078-0432.CCR-07-0162","volume":"13","author":"SS Ramalingam","year":"2007","unstructured":"Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA, Stoller RG, Potter DM, Argiris AE, Zwiebel JA, Egorin MJ, Belani CP (2007a) Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 13: 3605\u20133610","journal-title":"Clin Cancer Res"},{"key":"BF6605726_CR20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.canlet.2009.01.040","volume":"280","author":"J Schemies","year":"2009","unstructured":"Schemies J, Sippl W, Jung M (2009) Histone deacetylase inhibitors that target tubulin. Cancer Lett 280: 222\u2013232","journal-title":"Cancer Lett"},{"key":"BF6605726_CR21","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1158\/1078-0432.CCR-07-1786","volume":"14","author":"NL Steele","year":"2008","unstructured":"Steele NL, Plumb JA, Vidal L, Tjornelund J, Knoblauch P, Rasmussen A, Ooi CE, Buhl-Jensen P, Brown R, Evans TR, DeBono JS (2008) A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 14: 804\u2013810","journal-title":"Clin Cancer Res"},{"key":"BF6605726_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205\u2013216","journal-title":"J Natl Cancer Inst"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6605726.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605726","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605726.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:45:34Z","timestamp":1684413934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6605726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["BF6605726"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6605726","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}